Literature DB >> 29623342

Immune-mediated cholangitis: is it always nivolumab's fault?

Francesco Gelsomino1, Giovanni Vitale2, Andrea Ardizzoni2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29623342     DOI： 10.1007/s00262-018-2159-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  2 in total

1.  Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.

Authors:  Emanuel Raschi; Alessandra Mazzarella; Ippazio Cosimo Antonazzo; Nicolò Bendinelli; Emanuele Forcesi; Marco Tuccori; Ugo Moretti; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

2.  Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report.

Authors:  Rohit Agrawal; Grace Guzman; Saman Karimi; Pier Cristoforo Giulianotti; Alfredo Jose Mena Lora; Shikha Jain; Meshaal Khan; Brian R Boulay; Yolande Chen
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.